Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

310.77 -0.24 (-0.08%)
Official Closing Price Updated: 4:15 PM EDT, Jul 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,542,805
Open 310.25
Bid (Size) 310.61 (1)
Ask (Size) 311.95 (1)
Prev. Close 311.01
Today's Range 307.64 - 312.43
52wk Range 218.44 - 329.72
Shares Outstanding N/A
Dividend Yield 2.74%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What the Options Market Tells Us About Amgen
Via Benzinga
Amgen Unusual Options Activity
Via Benzinga

Performance

YTD
+4.50%
+4.50%
1 Month
+1.09%
+1.09%
3 Month
+12.51%
+12.51%
6 Month
+4.50%
+4.50%
1 Year
+38.11%
+38.11%

More News

Read More
1 Dividend Growth Stock to Buy and Hold for 10 Years
Via The Motley Fool
10 Blue-Chip Dividend Growth Stocks With 3% Yields And Safe Dividends
Via Talk Markets
These Are The Best Dow Jones Stocks Of 2024 Thus Far
Via Investor's Business Daily
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
Can Amgen Stock Keep Trouncing the S&P 500?
Via The Motley Fool
Topics Stocks
Exposures US Equities
Smart Money Is Betting Big In AMGN Options
Via Benzinga
Where Will Amgen Be in 5 Years?
Via The Motley Fool
Check Out What Whales Are Doing With AMGN
Via Benzinga
Tech Is Consolidating And The Market’s Seeking New Leadership
Via Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
Via Benzinga
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
Via FinancialNewsMedia
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
From FN Media Group LLC
Via GlobeNewswire
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
Via InvestorPlace
Expert Ratings For Amgen
Via Benzinga
Decoding Amgen's Options Activity: What's the Big Picture?
Via Benzinga
Market Whales and Their Recent Bets on AMGN Options
Via Benzinga
Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines
Via MarketBeat
Exposures COVID-19
Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks
Via Investor's Business Daily
3 Stocks to Buy as Ozempic Surges in Popularity
Via InvestorPlace
Why Big-Name Biotech Regeneron Pharma Just Joined The 1,000-Club
Via Investor's Business Daily
Skye Bioscience Pivots To Obesity After Glaucoma Flop; Shares Plummet
Via Investor's Business Daily
Is Geron Stock a Buy Following Its First New Drug Approval?
Via The Motley Fool
Amgen Seeks Expanded US Approval For Autoimmune Disease Drug Acquired Via $28B Horizon Deal
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.